Cabaletta Bio to Present at the Jefferies Healthcare Conference
May 31 2023 - 8:00AM
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology
company focused on developing and launching the first curative
targeted cell therapies for patients with autoimmune diseases,
today announced that Steven Nichtberger, M.D., Chief Executive
Officer, will present a company presentation at the Jefferies
Healthcare Conference on Wednesday, June 7, 2023 at 10:30 a.m. ET
in New York, NY.
A live webcast of the presentation will be available on the News
and Events section of the Company’s website at
www.cabalettabio.com. Replays of the presentation will be available
on the website for 30 days.
About Cabaletta BioCabaletta Bio (Nasdaq: CABA)
is a clinical-stage biotechnology company focused on the discovery
and development of engineered T cell therapies that have the
potential to provide a deep and durable, perhaps curative,
treatment for patients with autoimmune diseases. The CABA™ platform
encompasses two strategies: the CARTA (chimeric antigen receptor T
cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing
fully human CD19-CAR T, as the lead product candidate being
evaluated in systemic lupus erythematosus and myositis, and the
CAART (chimeric autoantibody receptor T cells) strategy, with
multiple clinical-stage candidates, including DSG3-CAART for
mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia
gravis. The expanding CABA™ platform is designed to develop
potentially curative therapies that offer deep and durable
responses for patients with a broad range of autoimmune diseases.
Cabaletta Bio’s headquarters and labs are located in Philadelphia,
PA.
Contacts:
Anup MardaChief Financial Officerinvestors@cabalettabio.com
Sarah McCabeStern Investor Relations,
Inc.sarah.mccabe@sternir.com
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Jul 2023 to Jul 2024